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Abstract – Purpose. The micronization using milling process to enhance dissolution rate is extremely 
inefficient due to a high energy input, and disruptions in the crystal lattice which can cause physical or 
chemical instability. Therefore, the aim of the present study is to use in situ micronization process through 
pH change method to produce micron-size gliclazide particles for fast dissolution hence better 
bioavailability. Methods. Gliclazide was recrystallized in presence of 12 different stabilizers and the effects 
of each stabilizer on micromeritic behaviors, morphology of microcrystals, dissolution rate and solid state of 
recrystallized drug particles were investigated. Results. The results showed that recrystallized samples 
showed faster dissolution rate than untreated gliclazide particles and the fastest dissolution rate was 
observed for the samples recrystallized in presence of PEG 1500. Some of the recrystallized drug samples in 
presence of stabilizers dissolved 100% within the first 5 min showing at least 10 times greater dissolution 
rate than the dissolution rate of untreated gliclazide powders. Micromeritic studies showed that in situ 
micronization technique via pH change method is able to produce smaller particle size with a high surface 
area. The results also showed that the type of stabilizer had significant impact on morphology of 
recrystallized drug particles. The untreated gliclazide is rod or rectangular shape, whereas the crystals 
produced in presence of stabilizers, depending on the type of stabilizer, were very fine particles with 
irregular, cubic, rectangular, granular and spherical/modular shape. The results showed that crystallization of 
gliclazide in presence of stabilizers reduced the crystallinity of the samples as confirmed by XRPD and DSC 
results.  Conclusion. In situ micronization of gliclazide through pH change method can successfully be used 
to produce micron-sized drug particles to enhance dissolution rate. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
It is well established that the active ingredient in a 
solid dosage form must undergo dissolution 
before it is available for absorption from the 
gastrointestinal tract. Many potential drug 
candidates are characterized by a low oral 
bioavailability. Often, poor drug dissolution and 
solubility rather than limited permeation through 
the epithelia of the gastrointestinal tract are 
responsible for low bioavailability of orally taken 
drugs. Therefore, the solubility of a drug is an 
important factor in determining the rate and extent 
of its absorption (1); and an enhancement in 
dissolution rate is important to attain suitable 
blood-levels of class II drugs (low solubility and 
high permeability). 
There are several methods for enhancing 
dissolution rate of poorly water-soluble drugs 
including producing solid dispersion (2-6), 
making liquisolid formulations (7-11) and milling 
or grinding of particles (12). The main 
mechanism behind the dissolution enhancement 
using the mentioned approaches is an increase in 
specific surface area of particle available for 
dissolution.  One of the most common techniques 
to increase surface area of drug particles hence 
dissolution rate is milling the particles (13). The 
milled particles have the tendency to agglomerate 
as a result of their hydrophobicity, thus reducing 
their available surface area (14). Milling process 
which is usually used to obtain small particles is 
the disruption of large crystals. The micronization 
process using mills is extremely inefficient (15) 
due to a high energy input, and disruptions in the 
crystal lattice that can cause physical or chemical 
instability (16, 17). 
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To overcome these problems, hydrophobic drugs 
can be microcrystallized using in situ 
micronization techniques (18). Micronized 
powders with a higher energetic surface show 
poorer flow properties (19). As the drug powders 
are prepared directly in micronized state during 
particle formation without any size reduction, this 
technique can be described as an in situ 
micronization technique (20). In situ 
micronization is a suitable method for the 
production of micron-sized drugs. Compared to 
milled products drug properties are optimized as 
all particle surfaces are naturally grown, the 
particle size is more uniformly distributed and the 
powder is less cohesive (21). 
One of the major challenges to drug 
development today is poor solubility, as an 
estimated 40% of all newly developed drugs are 
poorly soluble or insoluble in water (22). In 
addition, up to 50% of orally administered drug 
compounds suffer from formulation problems 
related to their high lipophilicity (23). Therefore, 
the aim of this study was to explore pH change 
method as an efficient approach to produce 
micron-sized particles in presence of twelve 
different stabilizers to enhance the dissolution and 
consequently the absorption of poorly water 
soluble drug, gliclazide. In the present study, solid 
state of recrystallized microparticles was also 
investigated using DSC, FT-IR and XRPD. 
 
MATERIALS AND METHODS 
 
Materials 
 
Gliclazide was purchased from CFM Co., Italy. 
All Brijs and PEGs were obtained from Fluka, 
Germany. Pluronic F68 (Sigma, UK), 
hydroxyethylcellulose (Aldrich, UK), PVP K30 
(BASF, Germany) and Carboxymethylcellulose 
(Aldrich, UK) were used. All the other reagents 
were of analytical grade.  
 
In Situ Micronization Technique 
 
Preliminary investigation 
In order to find ideal conditions for preparation of 
microcrystals (smaller particle size with less 
aggregation) using in situ microcrystallization 
through pH change technique, the preliminary 
studies were carried out. The aim of the 
preliminary study was to select the parameters 
such as the speed of homogenization, 
concentration of stabilizers and glicliazide and the 
type of stabilizers. In brief, the results showed 
that reducing pH from 11 to 5 by adding HCl 
within 5 min, while stirring with high sheer 
homogenizer at 26000 rpm, produced 
microcrystals without aggregation. The best 
concentration for any type of stabilizer and 
gliclazide concentration using the above condition 
were 0.05% and 0.3% (w/v) respectively. The 
results showed that type of stabilizer did not 
change the preliminary results. All experiments 
were carried out in 100 ml volume and ice bath 
temperature. 
 
Main crystallization procedure 
After the preliminary study as described above, 
the concentration of drug and stabilizers, speed of 
homogenization, range of pH, and temperature of 
the experiment to produce gliclazide 
microparticles with least aggregation were 
determined. So, the above parameters were kept 
constant with the exception of the type of 
stabilizer. On the basis of preliminary 
experiments, 0.3 g gliclazide was dissolved in 100 
ml of distilled water at pH 11 (pH was adjusted 
using 0.1N NaOH)  containing 0.05 g stabilizer.  
After complete dissolution of the drug under 
homogenization using a homogenizer with a 
speed of 26000 rpm (Heidolph, Silent crusher M, 
Germany) pH of the solution was reduced to 5 
within 5 min by the addition of HCl 0.1 N when 
the temperature of the solution was reached 
around 5 C. By reducing the pH of the solution a 
micron-size dispersion of drug was formed 
spontaneously due to low solubility of gliclazide 
at lower pH value. The mixture was allowed to be 
mixed in ice bath for 15 min and then it was 
transferred to the vacuum oven while stirring for 
3 hr. After that the aqueous suspension was frozen 
at –20°C and then it was freeze-dried (Christ-
Alpha 1-4, Braun Biotech-International-Germany) 
for 36 h. Particle size distribution of microcrystals 
was determined before and after freeze drying and 
there were no significant changes. In addition 
previous study showed no effect of freeze drying 
on particle size distribution (24). 
Preliminary results showed that a simple 
filtration technique cannot be used for the 
separation of particles as it was very slow process 
due to the high viscosity of the solution. 
Moreover, during the filtration and drying all 
particles stick firmly together which make 
particles difficult to disperse in dissolution 
medium. In the present study various grades of 
PEG (PEG 300, 600, 1500, 4000, 6000), 
hydroxyethylcellulose (HEC), carbo-
xymethylcellulose (CMC), different grades of Brij 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 12(3) 250 - 265, 2009 
 
 
 
 
252 
(Brij 35, 76, 97), pluronic F68 and PVP K30 were 
used as stabilizers. 
 
Scanning Electron Microscopy (SEM) 
 
Electron micrographs of crystals were obtained 
using a scanning electron microscope (LEO 440i, 
UK) operating at 15 kV. The specimens were 
mounted on a metal stub with double-sided 
adhesive tape and coated under vacuum with gold 
in an argon atmosphere prior to observation.  
 
Particle Size Analysis 
 
The size distribution of ground and unground 
powder was measured with a laser diffraction 
particle size analyzer (SALD-2101 Shimadzu, 
Japan). The particle size distribution and mean 
particle size diameter were automatically 
calculated using the software provided. The size 
distribution was evaluated with the span value 
defined as follows. 
 
Span = (D90%-D10%)/D50% Where, DN% (N= 10, 
50, 90) means the volume percentage of 
microparticles with diameters up to DN%. The 
smaller span value indicates the narrower particle 
size distribution. 
 
X-Ray Powder Diffraction (XRPD) 
 
X-ray diffractometery of drug, excipient and 
formulations were performed using Siemens 
diffractometer (Siemens, D5000-Germany). The 
cross section of samples was exposed to x-ray 
radiation (Cu Kα) with wavelength of 1.5406 Å. 
The rate of the scanning was 0.6˚ /min. Samples, 
ground into powders with an agate mortar and 
pestle, were measured on a low background 
quartz plate in an aluminium holder. 
 
Fourier Transform Infrared Spectroscopy 
 
Fourier-transform infrared spectroscopy was 
obtained on a Bomem 2000 T-IR system (Bomem 
Quebec, Canada) using the KBr disk method. 
Samples were mixed with KBr powder and 
compressed to 10-mm discs by hydraulic press at 
pressure of 150 bars for 30 s. The scanning range 
was 450– 4000 cm−1 and resolution was 4 cm−1. 
 
Thermal Analysis 
 
The DSC was calibrated with indium and lead 
standards, then samples of gliclazide crystals (3-6 
mg) were heated (range 30-200˚C) at a scanning 
rate of 10˚C/min in crimped aluminium pans 
using DSC instrument (Shimadzu DSC 60, Japan) 
under nitrogen gas. The thermograms were 
analysed in terms of melting point and enthalpy. 
 
Compressibility Index 
 
About 1 ml powder was carefully filled into a 
mounted measuring cylinder with known tare. 
The powder bed was leveled with a spatula, and 
the maximum bulk volume was read. A single tap 
was employed, and the volume was read again. 
This procedure was repeated, thereby gradually 
increasing the number of taps between individual 
readings, until three consecutive replicates of 100 
taps did not reduce the powder volume further. 
Hence the minimum powder volume (to give the 
maximum bulk density) had been reached. The 
measuring cylinder was then weighed to 
determine the powder mass. Compressibility 
index (25) was calculated using eq. 1: 
 
Compressibility percent = 100 × (ρt - ρa) / ρt    eq. 1 
 
Where ρt is the tapped density, ρa is the bulk 
density. All experiments were performed in 
triplicate. 
 
Dissolution Studies 
 
The USP paddle method (Erweka, DPT6R, 
Germany) was used for all the in vitro dissolution 
studies. In this method, the dissolution rate of 
gliclazide powders was measured at pH value of 
1.2.  The rate of stirring was 100 ± 2 rpm and the 
temperature of dissolution media was set at 37 ˚C. 
The powders were placed in 250 ml of HCl 0.1 N 
containing 0.25% Tween 80 and at appropriate 
intervals (5, 10, 15, 20, 30, 45, 60 and 90 min), 5 
ml of the samples were taken and filtered through 
a 0.45 μm Millipore filter. The dissolution media 
was then replaced by 5 ml of fresh dissolution 
fluid to maintain a constant volume. After proper 
dilution, the concentration of dissolved drug in 
the medium was determined spectro-
photometrically (Shimadzu, Japan) at 230. nm. In 
order to maintain sink conditions, Tween 80 was 
included to the dissolution medium and powders 
equivalent to 10 mg gliclazided was used in 
dissolution test.  Gliclazide is weak acid and its 
solubility in acidic medium is less than its 
solubility in alkaline medium. Therefore, the aim 
of the investigation was to increase 
solubility/dissolution rate of gliclazide in acidic 
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conditions (simulating gastric fluid). It is obvious 
that as gliclazide belongs to class II drugs (low 
solubility, high permeability), an increase in its 
acidic solubility increases the dissolution rate and 
hence its bioavailability.  This is why acidic 
condition was used to assess dissolution rate of 
gliclazide samples. 
For comparison purposes, physical mixtures 
were prepared by mixing of drug with different 
types of stabilizers using a spatula on a glass plate 
for 2 min. The mixture was then transferred to a 
glass bottle for further mixing (5 min). The 
mixtures were kept in glass bottle until use. 
Dissolution efficiency (%) up to 90 min 
(DE90min) was calculated according to eq. 2 (26): 
 
100%
100
0  
ty
dty
DE
t
    eq. 2 
 
Solubility Studies 
 
Solubility measurements were performed 
according to the method of Higuchi and Connors 
(27). In brief, solubility studies of different 
samples of gliclazide were carried out at pH 1.2. 
Saturated solutions were prepared by adding 
excess drug to the medium and shaking on the 
shaker (Velp, Italy) for 48h at 25 ± 0.5°C under 
constant vibration. After this period the solutions 
were filtered, diluted and analysed by UV-
spectrophotometer (Shimadzu, Japan). Three 
determinations were carried out for each sample 
to calculate the solubility of gliclazide.  
 
RESULTS 
 
Micronization of Gliclazide 
 
Preliminary studies showed that in absence of the 
stabilizer the particle size was larger than in the 
presence of a stabilizer. When the drug was 
recrystallized without any stabilizer the particle 
size was 50-100 µm. The results also showed that 
in absence of a stabilizer the tendency of particle 
to agglomerate is very high. Therefore, due to the 
presence of larger particles and aggregates no 
further studies were carried out on particles 
produced without a stabilizer. Furthermore, there 
are a few studies showed that the presence of 
stabilizer is necessary to produce microparticles 
of atrovastatin calcium (28) and disodium 
cromoglycatevital (29). On the basis of the 
preliminary studies under the following 
conditions microparticles of gliclazide with the 
least aggregation can be produced. The condition 
was as follows: the amount of stabilizer, stirring 
rate, drug concentration, time to change pH from 
11 to 5 were 0.05% (w/v), 26000 rpm, 0.3% (w/v) 
and 5 min respectively. Therefore, the above 
conditions were set up for all crystallization 
procedures in presence of various stabilizers. In 
the present study the effects of 12 different 
stabilizers namely; PEG with different molecular 
weights (PEG300, PEG 600, PEG 1500, PEG 
4000 and PEG 6000), various types of Brij (Brij 
35, Brij 76 and Brij 97), cellulose derivatives 
(HEC and CMC), PVP-K30 and pluronic F68 on 
micrometric, morphology and dissolution 
behavior of recrystallized gliclazide were 
investigated.  
 
Micromeritic Properties 
 
The micromeritic behaviors (mean particle size, 
span and Carr’s Index) of untreated gliclazide and 
recrystallized gliclazide in presence of various 
stabilizers are shown in Table 1. It is obvious 
from Table 1 that the original gliclazide 
(untreated drug) has larger mean particle size than 
all other gliclazide samples obtained via 
recrystallization technique. The smallest mean 
particle size was obtained for the sample 
recrystallized in presence of Brij 76.  Carr’s index 
which is an indication of powder flow behaviour 
showed that (Table 1), original gliclazide particles 
have lower Carr’s index values than treated 
samples.  
 
Morphology of Gliclazide Crystals 
 
As morphology of drug particles has an impact on 
micromeritic properties and dissolution behavior, 
so, the morphology of the recrystallized samples 
was investigated using scanning electron 
microscope (SEM). The results of this study are 
shown in Figure 1. As it is clear from Figure 1, 
the presence of stabilizer/additive in 
crystallization medium of gliclazide had 
significant effect on particle shape. The untreated 
gliclazide is rod or rectangular shape, whereas the 
crystals produced in the presence of stabilizers, 
depending on the type of stabilizer, were very fine 
particles (in some cases agglomeration of fine 
particles) with irregular, cubic, rectangular, 
granular and spherical/modular shapes. It can be 
concluded that the type of stabilizer had 
significant effect on drug particle morphology 
which is apparent from SEM results (Fig. 1). 
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Dissolution studies 
 
Dissolution profiles of untreated gliclazide and 
the crystals obtained in presence of various 
stabilizers are shown in Figures 2 to 5. For better 
comparison of dissolution profiles, dissolution 
data up to 15 min was plotted in Figures 2 to 5 
and dissolution efficiency was calculated up to 90 
min (Table 2). According to the results, the 
dissolution rates of all treated samples are 
remarkably faster than the untreated sample and 
the physical mixtures of the drug with stabilizers 
(P < 0.05).  
 
X-ray diffraction studies 
 
In order to investigate any changes in internal 
structure of crystallized gliclazide in presence of 
various additives, XRPD was used. Diffraction 
spectra of untreated gliclazide, gliclazide 
recrystallized in presence of additives and their 
physical mixtures are shown in Figure 6. The 
XRPD pattern of the gliclazide was very similar 
to that of the standard crystalline powder. 
Untreated gliclazide showed sharp peaks at 
diffraction angles of 2θ 10.5, 15, 17, 18, 22, 25 
and 26.3 which is in agreement with the literature 
(30). Most of these peaks are present in the 
diffractograms of physical mixture of gliclazide-
HEC (Fig. 6c) and gliclazide-CMC (Fig.6e) but 
with a smaller height than the standard crystalline 
powder. Figure 6 shows that the peak heights for 
recrystallized samples (Fig.6b and 6d) are pretty 
smaller than untreated sample and physical 
mixtures.  
Fourier transform infrared spectroscopy 
 
FT-IR spectra were used to further characterize 
the possibility of interactions between gliclazide 
and additives in the solid state. Figure 7 shows the 
FT-IR spectra of untreated drug, recrystallized in 
presence of PEGs and its physical binary 
mixtures. The spectra of all samples and all 
physical mixtures showed that they were 
identical.  
 
DSC studies  
 
The thermograms of untreated gliclazide and 
recrystallized microcrystals obtained in presence 
of HEC and CMC is shown in Figure 8. In order 
to have a better comparison between different 
samples in terms of enthalpy and melting point, 
the final results are listed in Tables 3 and 4. As 
the results show the Tm of the drug in all physical 
mixtures is almost the same but with a slight 
reduction in comparison with pure untreated 
gliclazide.  
 
DISCUSSION 
 
It seems that all stabilizers (additives) used in the 
present study acts as the crystal growth inhibitor. 
A stabilizing polymer usually covers the 
hydrophobic surfaces of the precipitated crystals 
and consequently due to the steric hindrance 
caused by the polymer prevents the crystal 
growth.  This indicated that it is possible to 
reduce particle size to less than 5 µm without 
using milling equipment. 
 
 
Table 1. Micromeritic properties of gliclazide samples recrystallized in presence of various 
stabilizers 
 
Formulation Mean Particle size (µm) Span Compressibility Index (%) 
Untreated drug 290.43 ± 36.05 2.10±0.20 20.04 ± 0.10 
PEG 300 3.69 ± 0.01 1.50±0.01 60.05 ± 0.52 
PEG 600 3.90 ± 0.00 1.40±0.03 60.23 ± 0.72 
PEG 1500 4.83 ± 0.11 1.64±0.02 60.01 ± 0.22 
PEG 4000 4.34 ± 0.14 1.65±0.01 60.00 ± 0.15 
PEG 6000 3.62 ± 0.12 1.35±0.01 50.05 ± 0.17 
Brij 35 4.76 ± 0.15 1.52±0.02 60.08 ± 0.36 
Brij 97 4.56 ± 0.23 1.32±0.01 60.16 ± 0.25 
Brij 76 3.09 ± 0.00 2.25±0.03 60.04 ± 0.53 
HEC 5.03 ± 0.11 3.41±0.02 50.06 ± 0.18 
CMC 3.73 ± 0.11 1.80±0.02 50.04 ± 0.16 
PVP K30 4.53 ± 0.15 2.62±0.01 50.02 ± 0.35 
Pluronic F68 3.59 ± 0.01 1.53±0.02 60.06 ± 0.10 
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Figure 1. Scanning electron micrographs of: (a) untreated gliclazide, and  microcrystals of gliclazide 
prepared in presence of stabilizer (b) PEG 300; (c) PEG 600; (d) PEG 1500; (e) PEG 4000; (f) PEG 6000; 
(g) HEC; (h)CMC; (i) Brij 35; (j) Brij76; (k) Brij 97; (l) PVP; (m) Pluronic F68. 
 
 
(a) (b) (c) 
(d) (e) (f)
(g) (h) (i) 
(j) (k) (l)
(m) 
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Table 2.  Dissolution and solubility data for physical mixtures of gliclazide-stabilizers and 
recrystallized gliclazide in presence of stabilizers. 
 
Formulation DE90min 
Recrystallized 
drug 
(%) 
 
DE90min 
Physical 
mixtures (%) 
 
Q5min 
recrystallized 
drug 
(%) 
 
Q5min 
Physical 
mixtures 
(%) 
Solubility 
(g/lit) 
Drug only*  38.7 ± 8.6 38.7 ± 8.6 12.7 ± 0.8 12.7 ± 0.8 0.025 ±0.012 
PEG 300 75.5 ± 6.0 44.5 ± 4.0 86.3 ± 10.6 20.2 ± 2.3 0.563 ± 0.041 
PEG 600 54 ± 6.7 65.9 ± 11.4 88.1 ± 8.6 35.6 ±5.5 0.407 ±0.067
PEG 1500 79.3 ± 1.3 28.2 ± 7.4 95.8 ± 1.1 11.1 ± 2.6 0.410 ± 0.005 
PEG 4000 83.2 ± 3.2 39.2 ± 10.9 76.1 ± 9.0 20.6 ± 3.3 0.453 ± 0.040 
PEG 6000 80.9 ± 1.7 50.3 ± 10.6 80.2 ± 6.9 32.5 ± 6.4 0.633 ±0.058 
Brij 35 78.1 ± 0.6 16.8 ± 9.3 89.8 ± 9.6 13.7 ± 3.0 0.673 ± 0.051 
Brij 76 72.8 ± 1.5 29.1 ± 2.1 72.3 ± 1.6 15.6 ± 0.7 0.437 ± 0.025 
Brij 97 72.4 ± 4.1 38.2 ± 1.2 71.2 ±4.9 15.2 ± 0.7 0.593 ± 0.050 
HEC 73.7 ± 3.3 41.4 ± 1.7 71.3 ± 2.5 29.9 ± 0.1 0.480 ± 0.006 
CMC 80.0 ± 7.0 30.7 ± 4.8 80.8 ±3.4 8.9 ± 1.7 0.400 ± 0.056 
PVP K30 81.3 ± 10.4 43.0 ± 1.2 66.3 ± 3.9 15.1 ±1.1 0.540 ± 0.061 
Pluronic F68 85.7 ± 12.1 40.2 ± 2.8 74.7 ± 9.8 13.4 ± 3.2 0.450 ± 0.062 
 
*untreated drug 
 
   
 
 
Table 3. Thermal analysis data obtained for untreated gliclazide and gliclazide 
samples produced in presence of various additives 
 
Formulation Onset temperature  
(ºC) Tm (ºC) enthalpy (J/g) 
Untreated drug 160.82±0.03 171.13±0.06 115.15±0.55 
PEG 300 140.99±0.11 158.50±0.20 26.62±0.43 
PEG 600 139.99±0.44 159.43±0.05 19.46±0.14 
PEG 1500 145.52±0.05 162.63±0.01 39.57±0.42 
PEG 4000 144.69±0.29 162.63±0.03 37.4±0.21 
PEG 6000 151.28±0.15 166.8±0.05 51.86±0.09 
Brij 35 153.76±0.05 164.28±0.01 17.26±0.25 
Brij 97 149.84±0.03 166.89±0.03 37.86±0.51 
Brij 76 142.54±0.13 163.00±0.04 45.23±0.41 
HEC 143.61±0.15 164.02±0.05 21.37±0.62 
CMC 147.12±0.08 165.69±0.04 38.31±0.53 
PVP K30 149.41±0.07 161.72±0.01 30.35±0.72 
Pluronic F127 154.73±0.02 167.70±0.06 78.27±0.31 
 
 
An increase in Carr’s index value for all treated 
samples is due to very high surface to mass ratio 
for fine particles which caused them to be more 
cohesive than coarser particles which are 
influenced more by gravitational forces. Powders 
having a particle size less than 10 µm are usually  
 
 
extremely cohesive and resist flow under gravity.  
Comparing flowability (Carr’s Index value) of 
various crystallized samples showed that 
gliclazide samples crystallized in the presence of 
PEG 6000, PVP, CMC and HEC have lower 
Carr’s index than other treated samples.  
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Figure 2. Dissolution behaviour of (a) 
recrystallized gliclazide in presence of stabilizers 
and (b) physical mixtures of drug-stabilizer. 
 
 
This could be due to the difference in shape of 
drug particles obtained in presence of different 
stabilizers which is apparent from SEM 
micrographs (Figure 1). Table 1 also shows that 
the presence of which stabilizer in crystallization 
medium produced narrower particle distribution 
(smaller value of span indicates narrower particle 
size distribution). It can be seen from the Table, 
apart from untreated sample and gliclazide 
crystals treated in presence of Brij 76, HEC and 
PVP, the rest of gliclazide crystal samples treated 
in presence of other stabilizers showed very 
narrow drug particle size distribution.   
 
Dissolution studies 
 
It is clear from the dissolution profiles (Figures 2 
to5) some of the recrystallized samples dissolved 
100% within the first 5 min showing at least 10 
times greater dissolution rate than the dissolution 
rate of untreated gliclazide powders. 
 
 
 
 
 
Figure 3. Dissolution behaviour of (a) 
recrystallized gliclazide in presence of stabilizers 
and (b) physical mixtures of drug-stabilizer. 
 
 
In order to investigate the effect of the type of 
stabilizer, DE90min and Q5min were calculated and 
the results are listed in Table 2. The lowest Q5min 
was obtained for untreated gliclazide and physical 
mixtures of untreated gliclazide and CMC, 
whereas the lowest DE90min was observed for 
physical mixtures of untreated gliclazide-Brij 35. 
Comparing the results of Q5min and DE90min for all 
studied samples revealed that there is a 
considrable increase in Q5min and DE for treated 
samples in presence of additives. For examples 
Q5min for gliclazide samples recrystallized in 
presence of PEG 1500 was 95.8%, whereas this 
value for original gliclazide crystals or physical 
mixtures of gliclazide-PEG 1500 was 12.7 and 
11.1% respectively.  
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Figure 4. Dissolution behaviour of (a) 
recrystallized gliclazide in presence of stabilizers 
and (b) physical mixtures of drug-stabilizer. 
 
 
By considering all data obtained in the present 
study it can be postulated that there should be 
three main factors responsible for an increase in 
dissolution rate of recrystallized gliclazide 
crystals; (a) an increase in surface area of drug 
particles; (b) an increase in wettability of drug 
particles and (c) an increase in saturated solubility 
of the treated drug particles. 
According to Noyes and Whitney equation 
(31), DR = [(DS (Cs-C)]/h, the drug dissolution 
rate (DR) is directly proportional to its 
concentration gradient (Cs-C) in the stagnant 
diffusion layer, diffusion coefficient (D) and its 
surface (S) available for dissolution. Cs is the 
saturation solubility of the drug in the dissolution 
medium and thus, it is a constant characteristic 
property related to the drug and dissolving media 
involved.  
 
 
 
Figure 5. Dissolution behaviour of (a) 
recrystallized gliclazide in presence of stabilizers 
and (b) physical mixtures of drug-stabilizer. 
 
 
Since all of dissolution tests for formulations 
were carried out at a constant rotational paddle 
speed (100 rpm) and identical dissolving media, 
we can assume that the thickness (h) of the 
stagnant diffusion layer and the diffusion 
coefficient (D) of the drug molecules remain 
almost identical. 
Since treated drug powders showed higher 
solubility than untreated drug and also the treated 
drug particles have higher surface area than 
untreated particles (SEM pictures) due to smaller 
particle sizes, therefore, the observed higher 
dissolution rates of recrystallized gliclazide are 
due to the significant increase in the specific 
surface area and saturated solubility (Table 2) of 
the treated drug powders. Specific surface area 
was not determined for all samples. Only two 
treated gliclazide samples and untreated sample 
were selected for the surface area measurement.  
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Figure 6. X-ray diffarction  patterns of (a)  untreated  gliclazide; (b) recrystallized gliclazide in presence of 
HEC; (c) physical mixture of gliclazide-HEC; (d) recrystallized gliclazide in presence of CMC; and (e) 
physical mixture of gliclazide-CMC. 
 
The results confirmed the above hypothesis as 
the specific surface area for recrystallized 
gliclazide in presence of Brij 35 and HEC 
appeared to be 18.06 and 17.56 m2/g, whereas 
untreated gliclazide had specific surface area of 
4.78 m2/g. The formation of fine drug particles in 
presence of stabilizers is due to the crystal growth 
inhibitory effect of stabilizers/additives used in 
the present study as described earlier in the paper 
(32-34). It has already been shown that wetting of 
the tablets or drug particle had important impact 
(I) 
(II) 
a 
d 
e 
d 
a 
e 
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Figure.7. X-ray diffarction patterns of (a) untreated GL, (b) microcrystal and (c) physical mixture prepared 
by pH change method using (I) PEG 300 and (II) PEG 600 as stabilizer.  
 
on dissolution of poorly water soluble drugs (10, 
35). 
Apart from crystal growth inhibitory effect of 
stabilizers, all of the additives used in the present 
study can also act as surface active agents and 
facilitate wetting of the drug particles by 
decreasing the interfacial tension between the 
dissolution medium and the drug. We believe that, 
therefore, in the present study due to significantly 
improved wetting properties of drug particles, the 
treated gliclazide samples display enhanced drug 
dissolution characteristics.  This in situ 
micronization has several advantages over milling 
techniques as unlike milling process the proposed 
process is not a high energy process which causes 
disruptions in the drug’s crystal lattice, resulting 
in the presence of disordered or amorphous 
regions in the final product (36). Furthermore, 
milled particles often show aggregation and 
agglomeration which results in poor wettability 
and thus poor dissolution (37). The results of 
present study showed that agglomeration or 
aggregation of drug particles can be minimized by 
controlling the crystallization conditions as 
described earlier in the preliminary results. 
 
Solid state studies 
 
The x-ray pattern showed that different samples 
produced different intensity of peaks. The peak 
height is affected by crystal size and crystallinity 
(12). Therefore, the peak height of the 
recrystallized drug powder is expected to be 
smaller than that of the standard crystalline
a 
b 
c 
(I) 
a 
b 
c 
(II) 
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Table 4. Thermal analysis data obtained for untreated gliclazide and physical 
mixtures of drug with /stabilizers 
 
Formulation Onset temperature  (ºC) Tm (ºC) enthalpy (J/g) 
Untreated drug 160.82±0.03 171.13±0.06 115. 15±0.49 
PEG 300 139.29±0.05 164.42±0.44 47.27±0.57 
PEG 600 141.75±0.09 164.32±0.53 56.96±0.86 
PEG 1500 148.84±0.51 168.49±0.75 63.97±0.11 
PEG 4000 151.45±0.12 170.49±0.06 79.38±0.17 
PEG 6000 151.95±0.01 170.71±0.64 73.74±1.32 
Brij 35 164.8±0.35 173.88±0.43 78.97±0.44 
Brij 97 167.45±0.19 175.58±0.22 95.2±0.09 
Brij 76 149.37±0.53 170.22±0.45 82.17±0.05 
HEC 147.65±0.08 168.76±0.64 82.21±0.75 
CMC 156.01±1.52 169.29±0.09 66.82±0.47 
PVP K30 160.29±1.25 173.14±0.73 75.43±0.04 
Pluronic F68 156.87±0.74 171.30±0.25 85.97±1.23 
 
 
 
Figure 8. FT-IR spectra of (I) recrystallized gliclazide samples and (II) physical mixtures of gliclazide in 
presence of (a) PEG 300 , (b) PEG 600, (c) PEG 1500, (d) PEG 4000, (e) PEG 6000, and (f) untreated 
gliclazide. 
(I) 
(II) 
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powder (mean particle size for untreated sample 
and spectrum b and c were 290, 3.69 and 3.09 µm 
respectively). Moreover, Figure 6 shows that the 
crystallinity of treated drug is lower than that of 
the standard gliclazide powder which is apparent 
from XRPD spectra (Fig. 6). The increased 
dissolution of treated gliclazide with respect to 
untreated drug powder partly can be attributed to 
the reduced crystallinity characterized by less 
intense peaks in the XRPD of treated samples. 
Similar results were obtained for the treated 
gliclazide samples in presence of other stabilizers 
which were not shown in the present article. As 
PEG 300 and 600 are liquids, any mixtures with 
these cosolvents may result in partial or complete 
solubilization of the drug. XRPD of the physical 
mixtures of PEG 300 and 600 with the API 
showed that the intensity of the peaks is only 
slightly smaller than physical mixtures of the API 
with solid excipients (compare Figures 6 and 7). 
This indicated that may be very little amount of 
gliclazide dissolved in PEG 300 or 600 as the 
concentration of the stabilizers was very low in 
these physical mixtures. 
The FT-IR spectra of all samples and all 
physical mixtures were identical (Fig. 8) and the 
main absorption bands of gliclazide appeared in 
all the spectra in the region of C=O sulphonylurea 
group absorption around 1711 cm−1. Similarly, the 
NH group located at 3265 cm−1 was not shifted. 
The sulphonyl group bands (S=O) are located at 
1348 cm−1 and 1163 cm−1 in unground gliclazide, 
and these were not shifted in the recrystallized 
gliclazide samples and physical mixtures spectra. 
This indicated that there was no difference 
between the internal structures and conformation 
of these samples at the molecular level. 
One useful technique to study of 
polymorphism is differential scanning calorimetry 
(DSC).  DSC is usually combined with XRPD to 
determine the polymorphic composition of 
pharmaceutical powders, when the polymorphs 
present have different melting points (Figure 9). 
The difference in melting point of gliclizide 
between different recrytallized samples and 
untreated gliclazide is more obvious than the 
difference between physical mixtures and pure 
gliclazide (Tables 3 and 4). For example, the 
lowest melting point for recrystallized samples in 
presence of PEG 300 was 158.5 0C, whereas this 
value for untreated gliclazide was 171.14 0C. The 
lower Tm for the physical mixtures and 
recrystallized samples in comparison with 
untreated gliclazide indicates the absence of any 
important incompatibility between the drug and 
stabilizers and suggests that the recrystallized 
microcrystals are not perfect crystals. Tables 3 
and IV also show a significant reduction in 
enthalpy changes particularly for the 
recrystallized samples in comparison with 
untreated gliclazide. A reduction in enthalpy of 
microcrystals has been reported for other drugs 
(38) as the presence of dissolved impurities 
(additives) may change the rate of crystallization 
and crystal habit by adsorbing the surface-active 
agents to the nuclei or growing crystals. The 
precipitated drug is sterically stabilized against 
crystal growth by adsorbed polymer and the 
surface energy and consequently the enthalpy of 
the system lowered. The lower enthalpy reported 
for recrystallized samples in presence of additives 
could partly be due to crystal habit of particles 
(39, 40). The modification of the physical 
properties of phenytoin by recrystallization from 
methanol exhibited increase in the specific surface 
area of the phenytoin crystals and a progressive 
change of crystal habit from needles to elongated 
plates. They reported that XRPD did not show 
any gross structural changes between needle and 
elongated phenytoin crystals. However, the 
enthalpy of fusion reduced by as much as 17° 
reflecting a significant change in both the 
enthalpy and entropy of the phenytoin crystals. It 
was shown that a reduction in the melting 
enthalpy of paraffin is directly correlated to the 
amount of paraffin in binary mixtures of paraffin-
EVA copolymer (41). Therefore, it can be 
concluded that the presence of small amounts of 
stabilizers in addition to the change in crystalline 
habit of the microcrystals is the cause of enthalpy 
reduction of the microcrystals compared to 
untreated drug.  
 
CONCLUSION 
 
The results of the present study showed that in 
situ micronization of gliclazide through pH 
change method can successfully be used to 
produce micron-sized drug particles to enhance 
dissolution rate. All recrystallized drug samples 
processed in presence of stabilizers showed fast 
dissolution rate than untreated drug and physical 
mixtures of drug-stabilizer. The type of stabilizer 
had significant effect of morphology of particles, 
hence on flow and particle size distribution. The 
results showed that crystallization of gliclazide in 
presence of stabilizers reduced the crystallinity of 
the samples as confirmed by XRPD and DSC 
results.   
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Figure 9. DSC thermograms of untreated gliclazide and recrystallized gliclazide in presence of HEC and 
CMC (for entlapy and melting point data fr all treated and physical mixtures refer to Tables 3 and 4). 
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